PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 296.7K (Avg.)
-1.36 | -1.31
View analysts' price targets and recommendations, and compare them with competitors.
$11.07
Higher upside than AXSM's upside of 56.00%.
Buy
Equal to AXSM's analyst recommendation of Buy.
Analyze analyst forecasts for the company and compare them with competitors.
19.40M
Worse than AXSM's estimated revenue of 1.50B.
-3.88M
Worse than AXSM's estimated ebitda of 351.60M.
-0.87
Worse than AXSM's estimated eps of 9.54.
-26.16M
Worse than AXSM's estimated net income of 433.57M.
-3.88M
Worse than AXSM's estimated ebit of 344.00M.
718.99M
Better than AXSM's estimated sg&a expense of 2.22B.
Analyze DCF forecasts for the company and compare them with competitors.
No Data
No DCF data available for this metric in the selected year.
No Data
No DCF data available for this metric in the selected year.
-21.77M
Better than AXSM's ebitda of -99.06M.
100.00%
Equal to AXSM's ebitda margin of 100.00%.
-22.21M
Better than AXSM's ebit of -99.14M.
100.00%
Equal to AXSM's ebit margin of 100.00%.
447.00K
Worse than AXSM's depreciation of 77.72K.
63.56M
Worse than AXSM's total cash of 183.88M.
100.00%
Equal to AXSM's cash as percentage of revenue of 100.00%.
No Data
No DCF data available for this metric in the selected year.
100.00%
Equal to AXSM's receivables as percentage of revenue of 100.00%.
No Data
No DCF data available for this metric in the selected year.
100.00%
Equal to AXSM's inventories as percentage of revenue of 100.00%.
4.34M
Better than AXSM's accounts payable of 13.50M.
100.00%
Equal to AXSM's payables as percentage of revenue of 100.00%.
-253.00K
Better than AXSM's capital expenditure of -45.89K.
100.00%
Equal to AXSM's capex as percentage of revenue of 100.00%.
4.99%
Better than AXSM's weighted average cost of capital (wacc) of 9.92%.
5.02%
Better than AXSM's cost of equity of 10.17%.
4.08%
Better than AXSM's cost of debt of 4.26%.
-0.23
Better than AXSM's beta of 1.25.
30.07M
Better than AXSM's diluted shares outstanding of 45.43M.
1.57M
Better than AXSM's total debt of 186.37M.
49.31M
Worse than AXSM's total equity of 4.18B.
50.89M
Worse than AXSM's total capital of 4.36B.
3.09%
Better than AXSM's debt weighting of 4.27%.
96.91%
Better than AXSM's equity weighting of 95.73%.
-22.04M
Better than AXSM's ebiat of -101.54M.
-17.50M
Better than AXSM's unlevered free cash flow of -98.95M.
2.00%
Equal to AXSM's long-term growth rate of 2.00%.
No Data
No DCF data available for this metric in the selected year.
No Data
No DCF data available for this metric in the selected year.
-71.33M
Worse than AXSM's net debt of -199.82M.
71.33M
Worse than AXSM's equity value of 6.33B.
2.37
Worse than AXSM's equity value per share of 139.31.